Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research focused on Multiple sclerosis and Prodromal Stage, with related work in Tolerability, Cohort, CD137. Notable publications include 'Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease', 'Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial', and 'International consensus on quality standards for brain health-focused care in multiple sclerosis'.
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
Toward mechanistic medical digital twins: some use cases in immunology
Forum on immune digital twins: a meeting report
Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
Real-world data on eculizumab treatment in NMOSD: high efficacy and potential challenges (P13-5.017)
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
Associations of<scp>sNfL</scp>with clinico‐radiological measures in a large<scp>MS</scp>population
Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis
International consensus on quality standards for brain health-focused care in multiple sclerosis
Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology
Multiple sclerosis registries in Europe – An updated mapping survey
Predictors of response to opicinumab in acute optic neuritis
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
Perceptions on the value of bodily functions in multiple sclerosis
The importance of collecting structured clinical information on multiple sclerosis
Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease